| Patient | Sugar Ray Robinson |
|---|---|
| Date of birth | 1963-05-03 |
| Identifiers | MRN HR-BX003-SYN; SSN (made up) 000-03-9318 |
| Document date | 2026-07-21 |
| Author | Langston Pryce-Okonjo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review of memory loss, seen the same day by cognitive neurology. [S]
Sugar Ray Robinson returns two weeks after intake with his care partner and is seen the same day by Dr. Haddad-Kowalski at the memory clinic. He had a brain MRI and a hearing test this morning. His intake blood count, kidney function, B12 and TSH were normal; hemoglobin A1c was 6.4%. He has slept well since stopping the over-the-counter sleep aid. He has not driven since intake; his care partner drives. The handgun stays unloaded and locked with the key held by his care partner. He repeated one question twice during the visit and laughed about it. [S]
| Element | Detail |
|---|---|
| MMSE | 22 |
| CDR | Global 1, sum of boxes 5.5 |
| MRI | Hippocampal atrophy; six microbleeds; no superficial siderosis; cavum septi pellucidi |
| Audiometry | Mild to moderate bilateral high-frequency hearing loss |
| Sleep | Sleeping well without diphenhydramine |
| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Memory loss; no headaches, weakness, tremor, falls or change in walking |
| Psychiatric | Negative | No low mood, hallucinations, suspiciousness or irritability |
| Ears, nose, mouth, and throat | Positive | Asks people to repeat themselves in noisy rooms |
| Endocrine | Negative | No low glucose spells he or his care partner has noticed |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1,000 mg oral tablet, one tablet twice daily with meals | One tablet twice daily with meals | Oral route | 2024-03-01 | active | S |
| Glipizide 5 mg oral tablet, one tablet before breakfast | One tablet before breakfast | Oral route | 2025-01-15 to 2026-08-18 | completed | S |
| Lisinopril 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2023-06-01 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2024-03-01 | active | S |
| Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counter | One capsule at bedtime | Oral route | 2025-10-01 to 2026-07-07 | stopped | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-21 | Body height | 180 | cm | S |
| 2026-07-21 | Body weight | 76.8 | kg | S |
| 2026-07-21 | Body mass index (BMI) [Ratio] | 23.7 | kg/m2 | S |
| 2026-07-21 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-21 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-07-21 | Heart rate | 70 | /min | S |
| 2026-07-21 | Respiratory rate | 14 | /min | S |
| 2026-07-21 | Body temperature | 36.6 | Cel | S |
| 2026-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-21 | Mini-Mental State Examination [MMSE] | 22 | {score} | S | ||
| 2026-07-21 | Clinical Dementia Rating scale [CDR] | 1 | {score} | S |
Vital signs recorded on 2026-07-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and cheerful; blood pressure 128/78; pulse 70; weight 76.8 kg |
| Neurological | Cranial nerves normal; no rigidity, tremor or slowness; normal strength and reflexes; steady narrow-based gait; no dysarthria |
| Mental status | Alert and courteous; repeats questions; mood good; no psychotic symptoms |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be found | active | confirmed | R41.3 | S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age. |
| Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylurea | active | confirmed | E11.9 | S — Synthetic modern diabetes anchored to his documented diabetes. |
| Hypertension, controlled on lisinopril | active | confirmed | I10 | S — Synthetic modern hypertension anchored to the single press report. |
| Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometry | active | confirmed | H90.3 | S — Synthetic finding checked as a modifiable contributor to cognitive difficulty. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA, MMSE) | At diagnosis, then yearly, or sooner with change | Completed today | MoCA 18 at intake; MMSE 22 today |
| Survey | Dementia staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Completed today | Global CDR 1 (sum of boxes 5.5); independent in personal care, needs help with bills, medicines and appointments (Functional Activities Questionnaire 11) |
| Laboratory | Reversible causes: blood count, metabolic panel, B12, TSH, depression, sleep apnea, hearing | Once at diagnosis | Completed today | Blood count, metabolic panel, B12 352 pg/mL and TSH 1.9 at intake, normal; PHQ-9 4; diphenhydramine stopped; STOP-Bang 2 (low risk of sleep apnea); hearing loss on audiometry today |
| Imaging | Brain MRI | Once at diagnosis; repeat only with an acute change | Completed today | Moderate hippocampal atrophy; six microbleeds; no siderosis or infarct; cavum septi pellucidi |
| Imaging | Amyloid biomarker confirmation (PET or CSF) | Once, when it will change diagnosis or treatment | Ordered | Amyloid PET booked in two weeks |
| Medication safety | Anti-amyloid antibody eligibility (lecanemab, donanemab), APOE genotyping and ARIA MRI schedule | At diagnosis of MCI or mild dementia due to Alzheimer's disease | Not indicated | Not a candidate: more than four cerebral microbleeds exclude lecanemab and donanemab under both appropriate use recommendations; APOE genotyping therefore not needed for treatment and offered only with counseling (declined); no ARIA monitoring schedule |
| Medication safety | Medicine review for anticholinergic and sedating drugs (Beers) | Every visit | Completed today | Diphenhydramine stopped at intake; no other anticholinergic or sedating drugs |
| Survey | Behavioral and psychological symptoms (NPI-Q items) | Every visit | Completed today | None: no agitation, apathy, low mood, anxiety, hallucinations, delusions or sleep disturbance |
| Medication safety | Cholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulse | Each follow-up and each dose change | Not indicated | Not started until the cause is confirmed |
| Self-management | Driving, firearm and home safety | At diagnosis and each follow-up | Completed today | Not driving; handgun unloaded and locked with the key held by his care partner; no wandering |
| Self-management | Care partner support and burden (Zarit, narrative) | At diagnosis, then at least yearly | Due | At the diagnosis visit |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Due | Planned at the preventive visit |
| Laboratory | Hemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia review | Every three months after a therapy change; every six months when stable | Up to date | 6.4% at intake; no low readings |
| Examination | Blood pressure, goal under 130/80 mmHg | Every visit | Completed today | 128/78 mmHg on lisinopril |
| Laboratory | Potassium and creatinine on lisinopril and metformin | Yearly, and after acute illness or dehydration | Up to date | Potassium 4.4 mmol/L, creatinine 1.0 mg/dL at intake |
| Examination | Dilated diabetic eye examination | Every one to two years without retinopathy | Referred | Requested at intake; appointment pending |
| Referral | Cognitive neurology consultation | At diagnosis | Completed today | Seen by Dr. Haddad-Kowalski today |
Goal progress:
Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); Lecanemab: Appropriate Use Recommendations (2023); Donanemab: Appropriate use recommendations (2025); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Practice Parameter update: Evaluation and management of driving risk in dementia (2010)
Follow-up: Amyloid PET in two weeks. Six-week review for results, with his care partner. Hearing aid assessment. Call with any new confusion, falls or low glucose readings. Next scheduled visit 2026-08-18: six-week review: amyloid PET result, the diagnosis and the plan, with diabetes, driving, firearm and caregiver support. [S]